June 24, 2015 | The Israeli medical aesthetics company PhotoMedex sold its XTRAC division for the treatment of vitiligo and psoriasis to Mela Sciences for $42.5 million. The acquisition will help PhotoMedex recover the debt from its acquisition of LCA opthalmological clinics. PhotoMedex is headquartered in Montgomeryville, Pennsylvania and is headed by CEO Dolev Rafaeli.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments